Virtual Library
Start Your Search
O. Ercelep
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-040 - Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single Center Experience (ID 9925)
09:30 - 09:30 | Author(s): O. Ercelep
- Abstract
Background:
Epidermal growth factor receptor (EGFR) mutation is seen 15-20% in non-small cell lung carcinomas (NSCLC), more common in non-smokers, female sex and Asian population. Treating NSCLC patients having activating EGFR mutations with tyrosine kinase inhibitor (TKI) significantly prolongs progression-free survival compared to standard chemotherapy and is a more tolerable. Our aim is to evaluate clinicopathologic features of patients using EGFR directed therapies (erlotinib or gefitinib) longer than 1 year.
Method:
Files of 46 patients with metastatic NSCLC having activating EGFR mutations and treated with EGFR TKI between 2012-2017 were retrospectively evaluated. Statistical analysis was done by SPSS 16.
Result:
Median age was 61 (30-80), and 56.5% (26/46) was female. Mean follow-up was 38 months.The rate of smoking was 41% (19/46). LDH elevation was found in 67% and CEA elevation was found in 50% of the patients at presentation. Median progression-free survival time (mPFS) was 21 months (range 2-58). mPFS is 21 months (2-35) for patients using erlotinib in first line (35 patients), and 13 months (5-30) in second line setting (11 patients). Sixty four percent of patients had exon 19 deletion, 28% had exon 21 mutation, and 8% had activating exon 18 mutations. There were 27 patients with PFS 12 months or more and 9 patients with less than 12 months. No statistically significant difference was found for PFS when clinicopathologic features (age, gender, 1st or 2nd line usage, LDH or CEA levels, ECOG PS, smoking, weight loss, mutation status) of these patients were compared. Median overall survival time (mOS) for metastatic disease was 39 months (range 4-65). The negative effect of ECOG-PS on OS was shown by univariate and multivariate analysis. Skin toxicity was observed in 18 patients (43%), while treatment was interupted and dose was reduced in 6 patients (14%) due to side effects.
Conclusion:
Activating mutation in EGFR is the most important marker that predicts response to EGFR-TKIs in NSCLC. Smokers should be tested for EGFR mutations, as some patients may benefit from EGFR-TKI treatment for longer than reported in the literature.
